IM Cannabis Corp. filings document a foreign private issuer reporting on Form 6-K, with disclosures centered on its medical cannabis operations in Israel and Germany, material agreements, capital structure and governance. Recent reports cover convertible note and warrant financings, common share conversion terms, registration-statement incorporation by reference, Nasdaq minimum bid price compliance, and executive officer changes.
IMCC regulatory filings also include shareholder-meeting notices, board and management matters, risk-factor and regulatory disclosures, and operating or financial-result updates. The filings describe how financing instruments, common shares, warrants, listing requirements and governance actions affect the company’s public-company reporting framework.
IM Cannabis Corp.'s preliminary Form F-3 covers up to 2,799,276 common shares for resale by selling shareholders; sales may begin only after the registration statement is effective. The shares include shares issued or issuable upon conversion of promissory notes, shares underlying warrants, creditor shares and shares tied to October 2026 debt-settlement notes and warrants. The company will not receive proceeds from selling-holder resales, but will receive exercise-price proceeds if the PIPE, creditor pre-funded and October 2026 settlement warrants are exercised; exercise proceeds are intended for general corporate purposes.
Common shares outstanding were 1,647,494 as of October 7, 2026; the resale maximum is approximately 170% of that count. If the PIPE and October 2026 notes convert in full and the PIPE, October 2026 settlement and creditor pre-funded warrants are exercised in full, outstanding shares would rise to 4,408,146, an approximately 170% increase. The instruments generally include 4.99% beneficial-ownership limits; holders of PIPE warrants may increase that limit, but not above 9.99%.
IM Cannabis Corp. (IMCC) completed the sale to Slil.com Holding Ltd. of all issued and outstanding shares of IMC Holdings Ltd. on September 29, 2026. Consideration consisted of a C$3,000,000 advance payment previously made by Slil and its acquisition of IMC Holdings, with certain liabilities remaining obligations of IMC Holdings. The agreement set a C$9,400,000 ceiling on aggregate Retained Liabilities, subject to mutual adjustment; that ceiling excludes direct liabilities of the Target Subsidiaries. Before closing, IMC Holdings transferred IM Cannabis’s Israeli operations out in a reorganization, and IM Cannabis retained them.
Based on management’s current unaudited pro forma analysis, IM Cannabis expects an approximately C$3 million improvement in shareholders’ equity; the actual accounting impact may differ and will be reflected in the applicable financial statements. Slil is beneficially owned and controlled by Oren Shuster, IM Cannabis’s Chief Executive Officer, director, securityholder and debtholder, making the sale a related party transaction under MI 61-101. Oren Shuster declared his interest and did not participate in or vote on approval. A special committee of independent directors recommended approval, and the company relied on financial-hardship exemptions from formal valuation and minority approval requirements.
IM Cannabis Corp. (IMCC) common shares are reported as beneficially owned by L.I.A. Pure Capital Ltd., the reporting person. It reported beneficial ownership of 164,585 shares, or 9.99% of the class, with sole voting and dispositive power over 164,585 shares. The percentage was calculated using 1,647,494 common shares issued and outstanding as of September 24, 2026.
IM Cannabis Corp. is the issuer whose common shares J.B.D Innovation Ltd. reported beneficially owning: 164,585 shares, or 9.99%. J.B.D Innovation Ltd. reported sole voting and dispositive power over those shares, with no shared voting or dispositive power. The percentage is based on 1,647,494 common shares issued and outstanding as of the date hereof, a figure provided by IM Cannabis Corp. Nissim Daniel is J.B.D Innovation Ltd.’s sole owner, sole director and Chief Executive Officer.
IM Cannabis Corp. (IMCC) is the issuer for a Schedule 13G in which Invest Pro Shukai Hon Ltd. reports beneficial ownership of 164,585 common shares, or 9.99%. The reporting person has sole voting and dispositive power over 164,585 shares and zero shared power in either category. The percentage calculation uses 1,647,494 issued and outstanding common shares, an amount the reporting person says the issuer provided. Eli Zamir, identified as a director, signed the statement.
IM Cannabis Corp. (IMCC) reported that director Einat Zakariya resigned from the board and all board committees, effective September 27, 2026. The company said she resigned for personal reasons and that her departure was not related to a disagreement about its operations, policies or practices.
IM Cannabis describes its medical cannabis platform as serving patients in Israel and Germany, with the German operations conducted through Adjupharm GmbH. Its Israeli subsidiaries import and distribute cannabis to medical patients and operate retail pharmacies and online platforms. The company also said it had entered an agreement, previously announced August 17, 2026, to sell I.M.C. Holdings Ltd.
IM Cannabis Corp. (IMCC) closed a registered direct offering, issuing 655,000 common shares at US$2.00 per share for US$1.31 million in aggregate gross proceeds before offering expenses. The company intends to use net proceeds for working capital and general corporate purposes, which may include evaluating potential additional business opportunities.
Invest-Pro - Shukai Hon Ltd. subscribed for 164,585 shares for US$329,170; Eli Zamir, an IM Cannabis director, is also an Invest-Pro director. The company treated this as a related-party transaction and relied on financial-hardship exemptions from formal valuation and minority shareholder approval requirements. The board and at least two-thirds of independent directors determined in good faith that IM Cannabis was in serious financial difficulty, the offering was designed to improve its financial position, and its terms were reasonable in the circumstances. Zamir disclosed his interest, did not participate in independent directors’ consideration, and abstained from voting. No special committee was established.
IM Cannabis Corp. is offering 655,000 Common Shares at US$2.00 each to certain accredited investors in a registered direct offering. It expects net proceeds of approximately US$1.3 million for working capital and general corporate purposes, potentially including evaluation of additional opportunities. Shares outstanding were 992,494 as of September 23, 2026, and are expected to be 1,647,494 after the offering. Delivery is expected on or about September 24, 2026, subject to closing conditions.
A definitive agreement provides for Slil.com Holding Ltd. to acquire IM Cannabis’s entire interest in I.M.C. Holdings Ltd., which will hold European-focused assets after reorganization; IM Cannabis says it will retain its Israeli operations. Consideration includes a previously received CAD$3.0 million advance and Slil’s assumption of certain liabilities not materially exceeding CAD$9.4 million, subject to adjustments. Closing is conditional, and the agreement may terminate if it has not occurred by September 30, 2026. A non-binding letter of intent proposes a 51% acquisition of Space Defense Innovations and a convertible credit facility of up to EUR2.3 million. Nasdaq confirmed regained minimum bid-price compliance on September 23, 2026.
IM Cannabis Corp. (IMCC) agreed to issue and sell 655,000 common shares at $2.00 per share in a registered direct offering to accredited investors. The offering is being made under the company’s existing Form F-3 shelf registration statement, declared effective by the SEC on July 9, 2025; a prospectus supplement is expected to be filed on or around September 24, 2026.
Gross proceeds will be approximately $1,310,000 before deducting offering expenses payable by the company. Closing is expected on or about September 24, 2026, subject to customary closing conditions. The proceeds are intended for working capital and general corporate purposes, which may include evaluating potential additional business opportunities. The offering is being made directly to investors, without a placement agent or underwriter.